绝经后2型糖尿病病人血糖波动与骨密度之间的相关性

doi:10.3969/j.issn.1003-9198.2021.08.007

摘要/Abstract

摘要： 目的本研究旨在探讨T2DM病人血糖波动与骨密度(BMD)之间的相关性。方法纳入88例绝经后女性T2DM病人为研究对象,入组病人均佩戴扫描式葡萄糖监测(FGM)仪器,并统计其生成的血糖波动指标,包括平均血糖(MBG)、目标范围内时间(TIR)、血糖标准差(SD)、血糖变异系数(CV)、平均血糖波动幅度(MAGE),分析T2DM病人BMD与生化指标、血糖波动指标之间的关系。结果随着BMD水平降低,病人年龄、病程、HbA1c、MBG、SD、CV、MAGE呈逐渐增加,BMI、25-羟维生素D3[25(OH)D3]和TIR水平逐渐降低,差异有统计学意义(P均＜0.05)。Pearson相关分析显示,HbA1c、SD、CV、MAGE与BMD呈负相关(r=-0.251、-0.317、-0.317、-0.288,P均＜0.05),BMD与TIR呈正相关(r=0.391,P＜0.001)。多元线性回归分析显示,TIR为BMD的影响因素(P＜0.05)。结论绝经后T2DM病人BMD水平与血糖波动指标存在相关性,低TIR可能是T2DM病人BMD降低的重要危险因素,减少血糖波动有助于延缓老年病人骨量下降。

关键词: 2型糖尿病, 骨密度, 血糖波动, 扫描式葡萄糖监测系统

Abstract: Objective To investigate the relationship of glycemic variability with bone mineral density (BMD) in the postmenopausal patients with type 2 diabetes mellitus(T2DM). Methods A total of 88 postmenopausal patients with T2DM were enrolled. All the patients accepted the detect of the flash glucose monitoring (FGM), and the mean blood glucose (MBG), the time in range (TIR), plasma glucose standard deviation (SD), glucose coefficient of variation (CV), and the mean amplitude of glycemic excursions (MAGE) were observed. Correlation between the biochemical indicator,glycemic variability and BMD was analyzed. Results With the decrease of BMD, the age, course of disease, glycosylated hemoglobin (HbA1c), SD, CV, MAGE were gradually increased, and body mass index (BMI), 25 (OH) D3 and TIR were decreased, with statistically significant (P<0.05). Pearson correlation analysis showed that HbA1c, SD, CV and MAGE were negatively correlated with BMD (r =-0.251, -0.317, -0.317, -0.288,all P<0.05), while BMD was positively correlated with TIR (r=0.391,P<0.001).Further, multiple linear regression analysis showed that TIR was a relevant factor of BMD (P<0.05). Conclusions Glycemic variability is related to BMD in the postmenopausal patients with T2DM, and TIR is independently and positively associated with BMD. Reducing glycemic variability may help delay the decline of bone mass.

Key words: type 2 diabetes mellitus, bone mineral density, glycemic variability, flash glucose monitoring system

中图分类号:

R 587.1

汪琳姣, 杨小华, 席巍, 袁晓岚. 绝经后2型糖尿病病人血糖波动与骨密度之间的相关性[J]. 实用老年医学, 2021, 35(8): 816-819.

WANG Lin-jiao, YANG Xiao-hua, XI Wei, YUAN Xiao-lan. Relationship of glycemic variability with bone mineral density in postmenopausal patients with type 2 diabetes mellitus[J]. Practical Geriatrics, 2021, 35(8): 816-819.

参考文献

[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017,10(5): 413-443.
[2] BONDS D E, LARSON J C, SCHWARTZ A V, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study[J]. J Clin Endocrinol Metab, 2006, 91(9): 3404-3410.
[3] SKRHA J, SOUPAL J, SKRHA J J R, et al. Glucose variability, HbA1c and Microvascular Complications[J]. Rev Endocr Metab Disord, 2016, 17(1): 103-110.
[4] SU G, MI S, TAO H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2011, 10:19.
[5] 史晓阳, 张颖超, 张珍, 等. 扫描式葡萄糖监测在住院患者血糖管理中的应用价值解析[J]. 中华糖尿病杂志, 2019, 11(5): 363-365.
[6] BATTELINO T, DANNE T, BERGENSTAL R M, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42(8): 1593-1603.
[7] American Diabetes Association.Standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S1-S212.
[8] 中华医学会内分泌学分会.糖尿病患者血糖波动管理专家共识[J]. 药品评价,2017, 14(17):5-9.
[9] CONWAY B N, LONG D M, FIGARO M K, et al. Glycemic control and fracture risk in elderly patients with diabetes[J]. Diabetes Res Clin Pract, 2016, 115:47-53.
[10] FERRARI S L, ABRAHAMSEN B, NAPOLI N, et al. Diagnosis and management of bone fragility in diabetes:an emerging challenge[J]. Osteoporosis International, 2018,29(12): 2585-2596.
[11] SIDDAPUR PR, PATIL A B, BORDE V S.Comparison of bone mineral density, T-scores and serum zinc between diabetic and non diabetic postmenopausal women with osteoporosis[J]. J Lab Physicians,2015,7(1): 43-48.
[12] EBRAHIMPUR M, SHARIFI F, NEZHAD F A, et al. Effect of diabetes on BMD and TBS values as determinants of bone health in the elderly: Bushehr Elderly Health program[J]. J Diabetes Metab Disord,2019, 18(1): 99-106.
[13] ALIKHANI M, ALIKHANI Z, BOYD C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways[J]. Bone, 2007, 40(2): 345-353.
[14] WOLDEN-KIRK H, OVERBERGH L, CHRISTESEN H T, et al. Vitamin D and diabetes: its importance for beta cell and immune function[J]. Mol Cell Endocrinol, 2011, 347(1/2): 106-120.
[15] Al-TIMIMI D J, AlI A F.Serum 25(OH) D in diabetes mellitus type 2: Relation to Glycaemic Control[J]. J Clin Diagn Res, 2013, 7(12): 2686-2688.
[16] 张奇, 蔡菁, 靳勇, 等. 中老年女性血清25羟维生素D水平与骨密度、体质量指数的调查研究[J]. 中国骨质疏松杂志, 2020, 26(3): 328-332.